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maintained within PDA-defined limits). Simulations were conducted in CORE dia-
betes model, which is a Markov model built on the base of published clinical trials
and encompasses over a dozen of diabetes complications. The model was exten-
sively validated and allows for reliable estimation of costs and outcomes associ-
ated with diabetes. Model inputs were adapted to Polish setting. Economic analysis
was conducted in lifetime horizon, costs and outcomes were discounted (5% and
3,5%, respectively). Cost acceptability threshold in Poland is 25 511 euro per QALY
gained. RESULTS: John’s QALY is 0,3 lower that QALY of Peter. Treatment of John’s
complications is 400 euro more expensive as compared to Peter. If willingness to
pay (WTP) equals to €7500 euro per QALY, yearly costs of Peter’s treatment may be
250 euro higher that John’s. If WTP is €15,000, Peter’s treatment may be €450 more
expensive that John’s and if WTP is €25,000 the difference in treatment costs may
be as high as 725 euro. CONCLUSIONS:DM2 treatment along with PDA recommen-
dations may be cost-effective provided additional costs do not exceed €725 per
year.
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INTRODUCTION: Good T2DM management requires not only good control of blood
glucose, but also blood pressure and serum lipid levels. Although data from the
Swedish National Diabetes Registry indicates that more patients have attained
recommended levels of these biomarkers over time, a sizable proportion fails to
meet all of these goals. OBJECTIVES: Assess the cost-effectiveness of intensifying
therapy to achieve Swedish-specific treatment goals for HbA1c, systolic blood pres-
sure (SBP), and LDL versus usual care for patients newly diagnosed with T2DM and
younger than fifty. METHODS: We used the Economic and Health Outcomes
(ECHO)-T2DM model, a Markov-based micro-simulation model, to simulate the
lifetimes of 500 cohorts of 500 hypothetical patients under two different scenarios:
1) treatment to maintain target goals for HbA1c, SBP and LDL; and 2) treatment to
maintain levels observed empirically in Sweden. Pharmacotherapy treatment
pathways for the control of hyperglycemia, hypertension and dyslipidemia fol-
lowed Swedish guidelines and were identical in the two scenarios. The costs of
pharmacotherapy and medical events were obtained from Swedish data.RESULTS:
Treatment to HbA1c, SBP and LDL goals versus treatment to observed levels in
Sweden resulted in a small QALY gain (0.13) and medical cost-savings of SEK
3552(€395). Spending on glucose-lowering agents, anti-hypertensives, and lipid-
lowering agents was increased by SEK 4136(€460), SEK 4864(€540) and SEK
2390(€265), respectively. Costs due to micro- and macrovascular complications
were reduced by SEK 5731(€637) and SEK 9522(€1058), respectively. CONCLUSIONS:
For patients newly diagnosed with T2DM and younger than fifty in Sweden, inten-
sifying therapy to maintain target glucose, blood pressure, and lipid levels resulted
in increased spending on pharmacotherapy, however, spending on micro- and
macrovascular events was reduced by a greater degree. These results suggest that
allocating more resources toward the attainment of these goals may be welfare-
improving.
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OBJECTIVES: To compare the cost-effectiveness of Follitropin Alpha (Gonal-F®),
which is a recombinant FSH, with a urinary highly purified hp-FSH (Menopur®)
used in assisted reproduction in Greece.METHODS:A decision tree in combination
with a Markov model was constructed to assess the clinical and economical impact
of comparators for three consecutives cycles. Transition probabilities for all stages
of a treatment cycle (i.e, cancelled ovum retrieval, successful recovery of oocytes
etc) were derived from literature and validated by clinical experts. Cost compo-
nents such as “initial treatment cost”, cost of “oocytes”, “oocyte pick-up”, “fertil-
ization”, “transfer”, “cryo preservation” and “frozen- thawed embryo transfer
(FET)” were derived from the electronic databases of selected private and public
clinics. The average number of units used per IVF and the rate of adverse events
were based on the literature. Drug prices and reimbursement tariffs, were obtained
from the “Government Gazette” and valued at 2011 prices. A probabilistic sensitiv-
ity analysis was performed to deal with uncertainty and to construct variability
measures. RESULTS: There was a statistically significant difference in favor of the
r-FSH arm compared to hp-HMG, which is associated with 52 more life births
(95%CI: 26-78, p-value0.001) per 1,000 patients. The cost per life birth was esti-
mated at €16,906 (95%CI: €16,347 – €17,516) and €17,286 (95%CI: €16,740 – €17,845) in
the r-FSH and hp-HMG arms, respectively. The cost per IVF was estimated at €4,365
(95%CI: €4,205 – €4,506) in the r-FSH and €3,815 (95%CI: €3,661 – €3,953) in hp-HMG
arm, indicating a difference at €550 (95%CI: €365 – €730, p-value0.001). The incre-
mental cost per life birth (ICER) for r-FSH versus hp-HMG was estimated at €14,540
(95%CI: €10,509 – €21,868), while the incremental cost per life year was estimated at
€4,153 (95%CI: €2,038 – €6,233). CONCLUSIONS: r-FSH may represent a cost-effec-
tive choice compared with a urinary hp-FSH (Menopur®) used for ovarian stimu-
lation in the Greek setting.
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OBJECTIVES: This study estimated the effect of weight reduction on long-term
outcomes and associated direct medical costs for patients newly diagnosed with
T2DM and less than fifty years old in Sweden. METHODS: We simulated the life-
times of 500 cohorts of 1000 patients with characteristics based on the Swedish
National Diabetes Register using the Economic and Health Outcomes (ECHO)-T2DM
model. All patients were assumed to increase weight over time (0.23 kg per year)
however, half of the patients were assumed to lose 5 kg in the first year, so that a 5
kg differential was maintained. The effect of weight on T2DM complications was
modeled using risk equations from the UK Prospective Diabetes Study, wherein
weight is only a direct determinant of the risk of congestive heart failure (CHF). The
risks of stroke and myocardial infarction are affected only indirectly via their link-
age with CHF, and mortality risk is affected only indirectly via macrovascular event
history. Weight change was assumed to impact QALYs by an amount reported in
the T2DM-specific CODE-2 study. Pharmacotherapy was administered according to
Swedish recommendations and Swedish cost data was used for medical events and
pharmacotherapy. RESULTS: A weight loss of 5 kg resulted in cost-savings of SEK
654 (€69) over an average of 17.1 years, mainly attributable to reductions in CHF
incidence. Life years increased marginally; QALYs, however, increased more sub-
stantially (0.18). CONCLUSIONS: At a relatively conservative willingness-to-pay
threshold of SEK 250,000 (€26,540), an intervention that resulted in a one-time
weight loss of 5 kg would be welfare improving at a cost of up to SEK 45,654 (€4,846)
over 17.1 years. As this simulation conservatively excluded a number of other
benefits of weight loss (e.g., effects via improved lipids, blood pressure and reduc-
tions in other weight-related illnesses), the true economic value is likely greater.
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OBJECTIVES: The aim of this economic evaluation was to test the hypothesis that
the clinical benefits observed with pioglitazone in the PROactive Study will lead to
economic benefits in terms of reduced macrovascular complications costs and
insulin treatment in Italy (the trial compared standard of care  pioglitazone ver-
sus standard of care alone).METHODS:Two analyses were undertaken; within trial
analysis and life-time simulation. The PROactive study provided the clinical and
resource utilization data to estimate the cost-effectiveness of pioglitazone in the
within trial analysis and was the basis for the secondary analysis which undertook
a life time simulation using a modified version of the validated CORE diabetes
model. CODE-II utility values were used for the base case. Due to the distribution
system of pioglitazone in Italy, two different prices were used; the public price paid
by the retail market (€2.11 per patient per day) and the ex-factory price discounted
by 25% (€ 0.96 per patient per day). Costs and health gains were discounted at the
joint rate of 3%. RESULTS: The incremental utility gain in within trial analyses was
0.0191, the incremental event and medication costs in the public price scenario
were €842 leading to an ICER of €43,996 per QALY. In the lifetime simulation model
the incremental utility gain was 0.149, the incremental event and medication costs
in the public price scenario were €3,783 leading to an ICER of €25,426 per QALY. In
the ex-factory price discounted by 25% scenario the medication costs were lower
leading to the inclusion of pioglitazone in treatment being dominant in both
analyses. CONCLUSIONS: In the Italian setting reduced costs for macrovascular
complications and insulin treatment leads to the inclusion of pioglitazone in treat-
ment being within standard cost-utility thresholds and is therefore an effective use
of health resources.
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OBJECTIVES: To estimate the long-term cost-effectiveness of transferring type 2
diabetes patients to an insulin detemir regimen therapy from a Neutral Protamine
Hagedorn (NPH) insulin regimen in the Portuguese routine clinical practice.
METHODS: A computer simulation model “CORE Diabetes Model” was used to
make long-term projections of clinical outcomes and direct medical costs based on
short term findings from the European cohort in the PREDICTIVE trial. Therapy
conversion to insulin detemir was associated with a reduction in glycosylated
haemoglobin (HbA1c) by 0.2% (p  0.05), mean body weight was reduced by 0.7 kg
(p0.01) and the incidence of total hypoglycaemia decreased from 11.7 to 3.0 epi-
sodes per patient/year (p  0.0001). Events were projected for a time horizon of 30
years. The cost analysis takes the perspective of the Portuguese National Health
System. RESULTS: Therapy conversion to insulin detemir plus OADs improves life
expectancy by 0.056 years and quality-adjusted life years (QALY) by 0.462 com-
pared to NPH insulin plus OAD. The incremental cost effectiveness ratio cost per
life years gained and per QALY gained with insulin detemir plus OADs treatment as
compared to NPH insulin plus OADs is 3,239€ and 393€ respectively. Type 2 diabetes
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